Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| moderate |
LUCENTIS 10 mg/mL, solution for injection provides a moderate improvement in actual benefit (level III) in terms of efficacy in comparison with VISUDYNE in the treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia. |
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
6kHhA1a9rGTD417b
Listen
